CD274 and non-small cell lung carcinoma: Since the results of the phase 3 trials Keynote 024 and Keynote 042, pembrolizumab monotherapy was approved as first-line therapy for PD-L1 1% NSCLC by the US Food and Drug Administration and for PD-L1 50% population by the European Medicines Agency [1,2].